Cargando…
Three‐year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus‐eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus‐eluting stent: A randomized controlled trial
AIMS: We compared long‐term clinical outcomes between patients treated with Orsiro sirolimus‐eluting stent (O‐SES) and those treated with durable biocompatible polymer Resolute Integrity zotarolimus‐eluting stent (R‐ZES). METHODS AND RESULTS: The ORIENT trial was a randomized controlled noninferiori...
Autores principales: | Kim, Soo‐Hyun, Kang, Si‐Hyuck, Lee, Joo Myung, Chung, Woo‐Young, Park, Jin Joo, Yoon, Chang‐Hwan, Suh, Jung‐Won, Cho, Young‐Seok, Doh, Joon‐Hyung, Cho, Jin Man, Bae, Jang‐Whan, Youn, Tae‐Jin, Chae, In‐Ho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754280/ https://www.ncbi.nlm.nih.gov/pubmed/31859438 http://dx.doi.org/10.1002/ccd.28654 |
Ejemplares similares
-
Elastic stent recoil in coronary total occlusions: Comparison of durable‐polymer zotarolimus eluting stent and ultrathin strut bioabsorbable‐polymer sirolimus eluting stent
por: Improta, Riccardo, et al.
Publicado: (2021) -
Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent
por: Jakobsen, Lars, et al.
Publicado: (2022) -
Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent
por: Jakobsen, Lars, et al.
Publicado: (2022) -
Individual patient data analysis of the BIOFLOW study program comparing safety and efficacy of a bioresorbable polymer sirolimus eluting stent to a durable polymer everolimus eluting stent
por: Toelg, Ralph, et al.
Publicado: (2020) -
One‐year clinical outcomes of patients treated with polymer‐free amphilimus‐eluting stents or zotarolimus‐eluting stents: A propensity‐score adjusted analysis
por: Rozemeijer, Rik, et al.
Publicado: (2019)